The company projects initial revenue generation from its Sildenafil Cream formulation in Q4 2025, backed by its 503B compounding strategy. Daré plans to provide updates in Q2 2025 on strategic ...
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients. U.S. regulators are trying to shut down the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback